BIOMAT Database Logo BIOMAT Database Logo

BCG immunotherapy of a mucous membrane malignant melanoma. Report of a case. 1976

M E Pliskin, and M J Mastrangelo, and R Bellet, and J Berkelhammer

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008297 Male Males
D008443 Maxillary Sinus The air space located in the body of the MAXILLARY BONE near each cheek. Each maxillary sinus communicates with the middle passage (meatus) of the NASAL CAVITY on the same side. Antrum of Highmore,Maxillary Antrum,Maxillary Ostium,Antrum, Maxillary,Highmore Antrum,Maxillary Antrums,Maxillary Ostiums,Sinus, Maxillary
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009163 Mycobacterium bovis The bovine variety of the tubercle bacillus. It is called also Mycobacterium tuberculosis var. bovis. BCG,Calmette-Guerin Bacillus
D009669 Nose Neoplasms Tumors or cancer of the NOSE. Cancer of Nose,Nasal Neoplasms,Nose Cancer,Cancer of the Nose,Nasal Cancer,Neoplasms, Nose,Cancer, Nasal,Cancer, Nose,Cancers, Nasal,Cancers, Nose,Nasal Cancers,Nasal Neoplasm,Neoplasm, Nasal,Neoplasm, Nose,Neoplasms, Nasal,Nose Cancers,Nose Neoplasm
D010255 Paranasal Sinus Neoplasms Tumors or cancer of the PARANASAL SINUSES. Cancer of Paranasal Sinus,Neoplasms, Paranasal Sinus,Paranasal Sinus Cancer,Cancer, Paranasal Sinus,Cancers, Paranasal Sinus,Neoplasm, Paranasal Sinus,Paranasal Sinus Cancers,Paranasal Sinus Neoplasm
D003601 Cytotoxicity Tests, Immunologic The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitized lymphocyte, an antibody, or complement. AHG-CDC Tests,Anti-Human Globulin Complement-Dependent Cytotoxicity Tests,Microcytotoxicity Tests,Anti Human Globulin Complement Dependent Cytotoxicity Tests,Anti-Human Globulin Complement-Dependent Cytotoxicity Test,Antiglobulin-Augmented Lymphocytotoxicity Test,Antiglobulin-Augmented Lymphocytotoxicity Tests,Cytotoxicity Test, Immunologic,Cytotoxicity Tests, Anti-Human Globulin Complement-Dependent,Cytotoxicity Tests, Immunological,Immunologic Cytotoxicity Test,Immunologic Cytotoxicity Tests,Lymphocytotoxicity Test, Antiglobulin-Augmented,Lymphocytotoxicity Tests, Antiglobulin-Augmented,Microcytotoxicity Test,AHG CDC Tests,AHG-CDC Test,Anti Human Globulin Complement Dependent Cytotoxicity Test,Antiglobulin Augmented Lymphocytotoxicity Test,Antiglobulin Augmented Lymphocytotoxicity Tests,Cytotoxicity Test, Immunological,Cytotoxicity Tests, Anti Human Globulin Complement Dependent,Immunological Cytotoxicity Test,Immunological Cytotoxicity Tests,Lymphocytotoxicity Test, Antiglobulin Augmented,Lymphocytotoxicity Tests, Antiglobulin Augmented

Related Publications

M E Pliskin, and M J Mastrangelo, and R Bellet, and J Berkelhammer
Adjuvant BCG immunotherapy for malignant melanoma.
October 1984, Canadian Medical Association journal,
M E Pliskin, and M J Mastrangelo, and R Bellet, and J Berkelhammer
[Immunotherapy of primary malignant melanoma of the palate with BCG: report of a case (author's transl)].
January 1975, Nihon Koku Geka Gakkai zasshi,
M E Pliskin, and M J Mastrangelo, and R Bellet, and J Berkelhammer
[Intratumor BCG immunotherapy of advanced malignant melanoma].
January 1981, Nowotwory,
M E Pliskin, and M J Mastrangelo, and R Bellet, and J Berkelhammer
BCG immunotherapy in patients with malignant melanoma.
June 1976, Archives of surgery (Chicago, Ill. : 1960),
M E Pliskin, and M J Mastrangelo, and R Bellet, and J Berkelhammer
Malignant melanoma of the nasal mucous membrane.
October 1979, The Journal of laryngology and otology,
M E Pliskin, and M J Mastrangelo, and R Bellet, and J Berkelhammer
Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
June 1977, The Australian and New Zealand journal of surgery,
M E Pliskin, and M J Mastrangelo, and R Bellet, and J Berkelhammer
Results of adjuvant BCG immunotherapy in malignant melanoma.
January 1981, Archiv fur Geschwulstforschung,
M E Pliskin, and M J Mastrangelo, and R Bellet, and J Berkelhammer
Pulmonary manifestations in patients with malignant melanoma during BCG immunotherapy. A preliminary report.
June 1979, Chest,
M E Pliskin, and M J Mastrangelo, and R Bellet, and J Berkelhammer
BCG immunotherapy in previously treated malignant melanoma patients.
June 1979, Biomedicine / [publiee pour l'A.A.I.C.I.G.],
M E Pliskin, and M J Mastrangelo, and R Bellet, and J Berkelhammer
[Malignant mucous primary sinonasal melanoma. A clinic case].
January 2007, Anales otorrinolaringologicos ibero-americanos,
Copied contents to your clipboard!